Interestingly, while investigating whether glutaminases function as prognostic biomarkers in human cancers, Saha et al. revealed that GLS and GLS2 expression can differentially modulate the clinical outcomes depending on the type of cancer [89]. This evidence concerns the gene GLS and cancer.